D-0559-2024 Class II Terminated
FDA drug recall D-0559-2024 was initiated by Lupin Pharmaceuticals Inc. on May 30, 2024 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications The recall status is terminated (terminated Apr 29, 2025). Affected quantity: 3,552 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Jun 26, 2024
- Initiation Date
- May 30, 2024
- Termination Date
- Apr 29, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,552 bottles
Product Description
Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03
Reason for Recall
Failed Content Uniformity Specifications
Distribution Pattern
Nationwide in the US
Code Information
Lot F201519, Expiry: November 2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0559-2024
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026